Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 158

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer’s Disease

Eriksdotter-Jönhagen, Maria, Linderoth, Bengt, Lind, Göran, Aladellie, Layth, Almkvist, Ove, Andreasen, Niels, Blennow, Kaj, Bogdanovic, Nenad, Jelic, Vesna, Kadir, Ahmadul, Nordberg, Agneta, Sundström, Erik, Wahlund, Lars-Olof, Wall, Anders, Wiberg, Maria, Winblad, Bengt, Seiger, Åke, Almqvist, Per, Wahlberg, Lars · 2012 · Dementia and Geriatric Cognitive Disorders

Abstract

Background/Aims: Degeneration of cholinergic neurons in the basal forebrain correlates with cognitive decline in patients with Alzheimer’s disease (AD). Targeted delivery of exogenous nerve growth factor (NGF) has emerged as a potential AD therapy due to its regenerative effects on the basal forebrain cholinergic neurons in AD animal models. Here we report the results of a first-in-man study of encapsulated cell (EC) biodelivery of NGF to the basal forebrain of AD patients with the primary objective to explore safety and tolerability. Methods: This was an open-label, 12-month study in 6 AD patients. Patients were implanted stereotactically with EC-NGF biodelivery devices targeting the basal forebrain. Patients were monitored with respect to safety, tolerability, disease progression and implant functionality. Results: All patients were implanted successfully with bilateral single or double implants without complications or signs of toxicity. No adverse events were related to NGF or the device. All patients completed the study, including removal of implants at 12 months. Positive findings in cognition, EEG and nicotinic receptor binding in 2 of 6 patients were detected. Conclusions: This study demonstrates that surgical implantation and removal of EC-NGF biodelivery to the basal forebrain in AD patients is safe, well tolerated and feasible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000336051

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 158

Metadata

Authors
Eriksdotter-Jönhagen, M., Linderoth, B., Lind, G., Aladellie, L., Almkvist, O., Andreasen, N., Blennow, K., Bogdanovic, N., Jelic, V., Kadir, A., Nordberg, A., Sundström, E., Wahlund, L.-O., Wall, A., Wiberg, M., Winblad, B., Seiger, Å., Almqvist, P., & Wahlberg, L.
Venue
Dementia and Geriatric Cognitive Disorders
Publisher
S. Karger AG
Published
2012
Volume
33
Issue
1
Pages
18-28
ISSN
  • 1420-8008 (ISSN-L)
  • 1421-9824
OpenAlex
W2005889466
Cited by
158
References
4
FWCI
8.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer’s Disease. https://app.cochat.ai/papers/10.1159/000336051
The paper
Eriksdotter-Jönhagen, M., Linderoth, B., Lind, G., Aladellie, L., Almkvist, O., Andreasen, N., Blennow, K., Bogdanovic, N., Jelic, V., Kadir, A., Nordberg, A., Sundström, E., Wahlund, L.-O., Wall, A., Wiberg, M., Winblad, B., Seiger, Å., Almqvist, P., & Wahlberg, L. (2012). Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders. https://doi.org/10.1159/000336051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.